One Size Doesn't Fit All: Why Your Weight Loss Plan Might Need a Complete Rethink

Two people with identical body mass index (BMI) scores might share a number but not the same disease. Recent scientific breakthroughs are revealing that obesity isn't a single condition with one cause, but rather multiple biological patterns that require completely different treatment approaches.

This discovery helps explain why the same diet, exercise plan, or medication can work remarkably well for one person while having little to no effect on someone else with the exact same BMI. The implications are huge: millions of people who blamed themselves for "failed" weight loss attempts may have simply been fighting the wrong battle with their biology.

What Makes Each Person's Weight Loss Journey Different?

Scientists now recognize that obesity can arise from distinctly different biological mechanisms. A new framework published in The Lancet Diabetes & Endocrinology proposes two categories: "preclinical obesity" and "clinical obesity," moving beyond BMI to focus on how excess body fat actually affects organ function.

The commission recommends evaluating 18 biological markers in adults, including blood sugar and cholesterol levels, along with direct measures of body fat distribution like waist circumference. For children, 13 specific indicators are assessed, including musculoskeletal problems that can affect their developing bodies.

"Two children may share the same body fat, the same BMI, but one is at much higher risk than the other," said Louise Baur, chair of child and adolescent health at the University of Sydney.

How to Identify Why Your Weight Loss Plan Isn't Working

The old "eat less, move more" advice was never wrong, but for many people, it was incomplete. Consider two patients with identical BMI scores but different underlying biology:

• Appetite Dysregulation: One person experiencing disrupted hunger signals might respond best to behavioral therapy, cognitive approaches, or medications that influence brain appetite centers
• Insulin Resistance: Another person whose obesity stems from insulin problems might respond better to GLP-1 medications like Ozempic or Wegovy, or treatments that improve insulin sensitivity
• Metabolic Adaptation: Some people's metabolism slows dramatically with weight loss, making regain almost inevitable without targeted intervention

This biological diversity explains why reality show contestants from "The Biggest Loser" experienced such dramatic weight regain despite incredible initial success. They weren't lacking discipline; their biology was working against the one-size-fits-all approach.

How New Medications Are Changing the Game

The rise of GLP-1 medications represents a shift toward targeting the biological mechanisms that drive weight gain rather than simply demanding more willpower. Eli Lilly's experimental drug retatrutide, dubbed the "triple G" drug, works by mimicking three hunger-regulating hormones rather than just one or two like existing treatments.

In late-stage trials, retatrutide helped patients lose an average of 23.7% of their body weight at 68 weeks when analyzing all participants. Among those who stayed on the drug, weight loss reached 28.7% on average. Some patients lost so much weight they chose to leave the study.

"It's incredible," said Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital. "Now, we have a drug that rivals the weight loss benefits of surgery."

However, roughly 18% of patients on the highest dose stopped treatment due to side effects, with common issues including nausea (43% of patients), diarrhea (33%), and vomiting (20.9%). The dropout rates were closely tied to patients' starting BMI, with some discontinuing due to "perceived excessive weight loss."

What This Means for Your Weight Loss Strategy

Understanding obesity as multiple distinct conditions changes everything about treatment. Instead of trial and error, future care could match interventions to individual biology from the start. This precision approach could reduce side effects, improve outcomes, and transform the often frustrating conversation between patients and healthcare providers.

"You can have obesity and yet be very healthy and you may never develop a medical problem," explained Robert Kushner, commission member and professor of medicine at Northwestern Feinberg School of Medicine. "But we called it 'preclinical obesity' because even in that situation, we know from other studies that if you wait long enough, there is a higher risk of developing medical problems."

The shift toward personalized obesity care represents more than just better medications or biological insights. It requires moving from quick fixes to continuous care, and from judgment to understanding. For the millions who have tried everything and blamed themselves, recognizing the biological complexity of obesity can be life-changing in itself.